NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free SILO Stock Alerts $1.82 -0.02 (-1.09%) (As of 12:17 PM ET) Add Compare Share Share Today's Range$1.79▼$1.8350-Day Range$1.51▼$2.1452-Week Range$1.22▼$3.05Volume4,486 shsAverage Volume177,330 shsMarket Capitalization$5.17 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Silo Pharma alerts: Email Address Silo Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside443.5% Upside$10.00 Price TargetShort InterestHealthy4.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 5 Articles This WeekInsider TradingAcquiring Shares$9,889 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSilo Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilo Pharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.51% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently increased by 87.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SILO. Previous Next 2.9 News and Social Media Coverage News SentimentSilo Pharma has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Silo Pharma this week, compared to 1 article on an average week.Search Interest5 people have searched for SILO on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,889.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.56% of the stock of Silo Pharma is held by insiders.Percentage Held by InstitutionsOnly 5.58% of the stock of Silo Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Silo Pharma Stock (NASDAQ:SILO)Silo Pharma. Inc., a developmental stage biopharmaceutical company, develops traditional therapeutics and psychedelic medicine. Its lead program includes SPC-15, an intranasal drug targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; and SP-26, a ketamine-based loaded implant indicated for fibromyalgia and chronic pain relief. The company's preclinical products include SPC-14 to treat Alzheimer's disease; and SPU-16, a central nervous system homing peptide targeting the central nervous system with indication in multiple sclerosis. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin and ketamine, as well as depression, mental health issues, and neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.Read More SILO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SILO Stock News HeadlinesMay 1, 2024 | msn.comMultiple sclerosis patients find hope in ‘liquid gold’April 30, 2024 | msn.com‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’May 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 25, 2024 | investing.comSilo Pharma reports promising SPC-15 study for PTSD therapyApril 25, 2024 | finance.yahoo.comSilo Pharma, Inc. (SILO) Stock Price, News, Quote & History - Yahoo FinanceApril 23, 2024 | finance.yahoo.comSilo Pharma Announces Positive Results for Intranasal PTSD TreatmentApril 23, 2024 | globenewswire.comSilo Pharma Announces Positive Results for Intranasal PTSD TreatmentApril 17, 2024 | msn.comPsyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & MoreMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 10, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease TherapeuticApril 10, 2024 | markets.businessinsider.comSilo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia UniversityApril 10, 2024 | finance.yahoo.comSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticApril 10, 2024 | globenewswire.comSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease TherapeuticMarch 20, 2024 | finance.yahoo.comSilo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticMarch 18, 2024 | globenewswire.comSilo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainMarch 14, 2024 | finance.yahoo.comGlobal Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033 | CAGR of 11.61%March 11, 2024 | msn.comElectoral bonds case: Supreme Court dismisses SBI’s appeal for extension of deadline, directs disclosure by March 12February 29, 2024 | morningstar.comSILO Pharma Inc SILOFebruary 28, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDFebruary 28, 2024 | globenewswire.comSilo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDFebruary 14, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 14, 2024 | finance.yahoo.comSilo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 14, 2024 | globenewswire.comSilo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 5, 2024 | nytimes.comExploring Ghana, With Contemporary Art as a GuideFebruary 1, 2024 | finance.yahoo.comSilo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyJanuary 24, 2024 | marketwatch.comSilo Pharma Sees Positive Data From Study for Alzheimer's TreatmentJanuary 24, 2024 | finance.yahoo.comSilo Pharma Announces Positive Results in Alzheimer’s Disease StudySee More Headlines Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Next Earnings (Estimated)6/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SILO CUSIPN/A CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+443.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,700,000.00 Net Margins-5,134.79% Pretax Margin-5,035.92% Return on Equity-46.23% Return on Assets-38.22% Debt Debt-to-Equity RatioN/A Current Ratio9.90 Quick Ratio9.90 Sales & Book Value Annual Sales$70,000.00 Price / Sales74.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book0.86Miscellaneous Outstanding Shares2,840,000Free Float2,686,000Market Cap$5.23 million OptionableNot Optionable Beta0.12 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Eric Weisblum (Age 54)Chairman, President & CEO Comp: $569.01kMr. Daniel E. Ryweck (Age 59)Chief Financial Officer Comp: $62.69kDr. James S. Kuo M.B.A. (Age 59)M.D., Vice President of Research & Development Key CompetitorsSynaptogenixNASDAQ:SNPXPalisade BioNASDAQ:PALIOpGenNASDAQ:OPGNFirst Wave BioPharmaNASDAQ:FWBISonnet BioTherapeuticsNASDAQ:SONNView All CompetitorsInsidersEric WeisblumBought 600 shares on 4/4/2024Total: $1,176.00 ($1.96/share)Eric WeisblumBought 1,100 shares on 4/1/2024Total: $2,101.00 ($1.91/share)Eric WeisblumBought 3,408 shares on 3/28/2024Total: $6,611.52 ($1.94/share)Eric WeisblumBought 500 shares on 12/19/2023Total: $815.00 ($1.63/share)Eric WeisblumBought 200 shares on 12/14/2023Total: $300.00 ($1.50/share)View All Insider Transactions SILO Stock Analysis - Frequently Asked Questions Should I buy or sell Silo Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silo Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SILO shares. View SILO analyst ratings or view top-rated stocks. What is Silo Pharma's stock price target for 2024? 1 brokerages have issued 12-month target prices for Silo Pharma's shares. Their SILO share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 443.5% from the stock's current price. View analysts price targets for SILO or view top-rated stocks among Wall Street analysts. How have SILO shares performed in 2024? Silo Pharma's stock was trading at $1.44 on January 1st, 2024. Since then, SILO shares have increased by 27.8% and is now trading at $1.84. View the best growth stocks for 2024 here. Are investors shorting Silo Pharma? Silo Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 115,000 shares, an increase of 87.3% from the March 31st total of 61,400 shares. Based on an average daily trading volume, of 216,600 shares, the short-interest ratio is currently 0.5 days. Currently, 4.5% of the shares of the company are sold short. View Silo Pharma's Short Interest. When is Silo Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 24th 2024. View our SILO earnings forecast. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SILO) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTracker Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
